Regulatory Exclusivity: PATENT CHALLENGE
✉ Email this page to a colleague
Drugs with Patent Challenge Regulatory Exclusivity
Click here to exclude patents covering these drugs from this list
Applicant | Tradename | Generic Name | NDA | Approval Date | Type | Patent No. | Patent Expiration | Exclusivity Expiration | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|
Apotex | DASATINIB | dasatinib | 202103 | Jun 10, 2016 | RX | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | PATENT CHALLENGE |
Apotex | DASATINIB | dasatinib | 203180 | Nov 23, 2021 | RX | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | PATENT CHALLENGE |
Hikma | HYDROMORPHONE HYDROCHLORIDE | hydromorphone hydrochloride | 216899 | Feb 9, 2024 | RX | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | PATENT CHALLENGE |
Ingenus Pharms Llc | IVABRADINE HYDROCHLORIDE | ivabradine hydrochloride | 214051 | Dec 30, 2021 | RX | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | PATENT CHALLENGE |
Rubicon | BACLOFEN | baclofen | 214445 | Dec 6, 2024 | RX | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | PATENT CHALLENGE |
>Applicant | >Tradename | >Generic Name | >NDA | >Approval Date | >Type | >Patent No. | >Patent Expiration | >Exclusivity Expiration | >Patented / Exclusive Use |